Nicolae Sarbu

Nicolae Sarbu

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in RadioGraphics
Verified
Journal Article
Closed access
NSNicolae Sarbu
Nicolae Sarbu
RSRobert Y. Shih
Robert Y. Shih
RJRobert V. Jones
Robert V. Jones
IHIren Horkayne-Szakaly
Iren Horkayne-Szakaly
LOLaura Oleaga
Laura Oleaga
JSJames G. Smirniotopoulos
James G. Smirniotopoulos
This article describes the imaging appearances of white matter diseases and the pathologic substrate responsible for the various imaging features. White matter diseases include a wide spectrum of disorders that have in common impairment of normal myelination, either by secondary destruction of previously myelinated structures (demyelinating processes) or by primary abnormalities of myelin formation (dysmyelinating processes). The pathogenesis of many white matter diseases remains poorly understood. Demyelinating disorders are the object of this review and will be further divided into autoimmune, infectious, vascular, and toxic-metabolic processes. Autoimmune processes include multiple sclerosis and related diseases: tumefactive demyelinating lesions, Balo concentric sclerosis, Marburg and Schilder variants, neuromyelitis optica (Devic disease), acute disseminated encephalomyelitis, and acute hemorrhagic leukoencephalopathy (Hurst disease). Infectious processes include Lyme disease (neuroborreliosis), progressive multifocal leukoencephalopathy, and human immunodeficiency virus (HIV) encephalopathy. Vascular processes include different types of small-...

1 February 2015 in Autoimmunity Reviews
Verified
Journal Article
Closed access
NSNicolae Sarbu
Nicolae Sarbu
FAFarah Alobeidi
Farah Alobeidi
PTPilar Toledano
Pilar Toledano
GEGerard Espinosa
Gerard Espinosa
IGIan Giles
Ian Giles
NBNuria Bargallo
Nuria Bargallo

1 October 2013 in Autoimmunity Reviews
Verified
Journal Article
Closed access
PTPilar Toledano
Pilar Toledano
NSNicolae Sarbu
Nicolae Sarbu
GEGerard Espinosa
Gerard Espinosa
NBNuria Bargallo
Nuria Bargallo
RCRicard Cervera
Ricard Cervera

10 April 2017 in Lupus
Verified
Journal Article
Closed access
NSNicolae Sarbu
Nicolae Sarbu
PTP Toledano
P Toledano
ACA Calvo
A Calvo
ERE Roura
E Roura
MSM I Sarbu
M I Sarbu
NBNuria Bargallo
Nuria Bargallo
The objective of this study was to determine whether advanced MRI could provide biomarkers for diagnosis and prognosis in neuropsychiatric systemic lupus erythematosus (NPSLE). Our prospective study included 28 systemic lupus erythematosus (SLE) patients with primary central NPSLE, 22 patients without NPSLE and 20 healthy controls. We used visual scales to evaluate atrophy and white matter hyperintensities, voxel-based morphometry and Freesurfer to measure brain volume, plus diffusion-tensor imaging (DTI) to assess white matter (WM) and gray matter (GM) damage. We compared the groups and correlated MRI abnormalities with clinical data. NPSLE patients had less GM and WM than controls (p = 0.042) in the fronto-temporal regions and corpus callosum. They also had increased diffusivities in the temporal lobe WM (p < 0.010) and reduced fractional anisotropy in the right frontal lobe WM (p = 0.018). High clinical scores, longstanding disease, and low serum C3 were associated with atrophy, lower fractional anisotropy and higher diffusivity in the fronto-temporal lobes. Antimalarial treatment correlated negatively with atrophy in the frontal cortex and thalamus; it was also associated with lower diffusivity in the fronto-temporal WM clusters. Atrophy and microstructural damage in fronto-temporal WM and GM in NPSLE correlate with severity, activity and the time from disease onset. Antimalarial treatment seems to give some brain-protective effects.

31 May 2022 in Medicina
Verified
Journal Article
Open access
PDF file
DSDANIELA Jicman STAN
DANIELA Jicman STAN
MSMIHAELA IONELA SARBU
MIHAELA IONELA SARBU
SFSilvia Fotea
Silvia Fotea
Alexandru NechiforAlexandru Nechifor
Alexandru Nechifor
BGBalan Gabriela
Balan Gabriela
Alin Laurentiu TATUAlin Laurentiu TATU
Alin Laurentiu TATU
Background and Objectives: Oral mucositis, a severe non-hematological complication, can be induced by chemoradiotherapy. It is associated with severe local dysfunction, severely affecting the patient’s quality of life; it increases the risk of oral infections and interrupts oncological treatment, thus prolonging the duration and cost of hospitalization. Besides all of the agents used in the prevention and treatment of oral mucositis induced by oncological treatment, can there be found an easier one to administer, with an effective preparation, high addressability, both for adults and paediatric patients, without side effects, and at the same time cheap and easy to purchase? The aim of the present paper is to demonstrate the existence of this product, which is available to everyone, having multiple benefits. Materials and Methods: For the purpose of writing this article, materials were searched in electronic databases in between 2019 and 2021, taking into consideration papers where authors have demonstrated the effectiveness of this product through its topical or systemic use. Results: Numerous studies have highlighted the benefits of honey on oral mucositis. Through its analgesic, anti-inflammatory, anti-cancerous and antibacterial action, honey has proved to have a major impact on the patient’s quality of life and nutritional status by promoting tissue epithelialization and healing of the chemoradiotherapy-induced lesions. Conclusions: Superior to many natural agents, bee honey can be successfully used in both preventing and treating oral mucositis. There are currently numerous studies supporting and recommending the use of bee honey in the management of this oncological toxicity.

1 September 2019 in Clinical Imaging
Verified
Journal Article
Closed access
NSNicolae Sarbu
Nicolae Sarbu
VLValentina Lolli
Valentina Lolli
JSJames G. Smirniotopoulos
James G. Smirniotopoulos